SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-011757
Filing Date
2022-08-03
Accepted
2022-08-03 07:30:53
Documents
76
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20220630x10q.htm   iXBRL 10-Q 1808320
2 EX-10.1 acrs-20220630xex10d1.htm EX-10.1 119852
3 EX-31.1 acrs-20220630xex31d1.htm EX-31.1 15592
4 EX-31.2 acrs-20220630xex31d2.htm EX-31.2 15612
5 EX-32.1 acrs-20220630xex32d1.htm EX-32.1 9484
6 GRAPHIC acrs-20220630xex10d1002.jpg GRAPHIC 798
7 GRAPHIC acrs-20220630xex10d1001.jpg GRAPHIC 715
  Complete submission text file 0001558370-22-011757.txt   7906959

Data Files

Seq Description Document Type Size
8 EX-101.SCH acrs-20220630.xsd EX-101.SCH 43533
9 EX-101.CAL acrs-20220630_cal.xml EX-101.CAL 50053
10 EX-101.DEF acrs-20220630_def.xml EX-101.DEF 210657
11 EX-101.LAB acrs-20220630_lab.xml EX-101.LAB 457572
12 EX-101.PRE acrs-20220630_pre.xml EX-101.PRE 329924
70 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20220630x10q_htm.xml XML 1558221
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 221130929
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences